Crit Care Nurse 2005 Oct; 25(5): 14-26
Cover Article
CE Article
The Implantable Hemodynamic Monitoring System
Theresa M. Wadas, MSN, CRNP, FNP, ACNP, CCRN
Theresa M. Wadas is a coordinator for the adult acute and continuing care nurse practitioner program at the University of Alabama at Birmingham, Birmingham, Ala.
To purchase electronic or print reprints, contact The InnoVision Group, 101 Columbia, Aliso Viejo, CA 92656. Phone, (800) 809-2273 or (949) 362-2050 (ext 532); fax, (949) 362-2049; e-mail, reprints{at}aacn.org.
*This article has been designated for CE credit. A closed-book, multiple-choice examination follows this article, which tests your knowledge of the following objectives:- Identify nursing care for patients with implantable hemodynamic monitoring systems (IHMSs)
- Describe the various implications for the use of IHMSs
- Discuss the differences between indirect and direct hemodynamic monitoring and physiological parameters of IHMSs
Heart failure is a clinical syndrome that affects 5 million persons in the United States and results in substantial morbidity and mortality. Despite advances in pharmacological management, 50% of patients with chronic heart failure will die within 5 years of the diagnosis. The progression of left ventricular dysfunction and severe symptomatic decompensation often requiring hospitalization remain essential features of the heart failure syndrome. Heart failure is responsible for 11 million visits to healthcare providers’ offices, causes or contributes to more than 3.5 million hospitalizations annually, and remains the leading cause of hospitalization for those 65 years or older. The estimated economic burden of heart failure is $20 billion to $40 billion per year. This amount includes the cost of care delivered by healthcare providers, expenses related to hospital and nursing home services, and the cost of medications, home health-care, and other medical durables.1
Managing patients with heart failure requires an accurate clinical assessment of the patients’ hemodynamic status. Subtle changes in volume status or intracardiac filling pressures may affect functional status, hemodynamic status, ventricular performance, and survival. In particular, elevated filling pressures (ie, increased jugular venous pressure, central venous pressure, right and left atrial and ventricular pressures, and pulmonary artery pressure) may lead to neurohormonal activation, which acts as a compensatory mechanism to support a failing heart. Without appropriate interventions, persistent neurohormonal activation leads to worsening cardiac function and deleterious outcomes of advanced heart failure.1
In order to prevent progression of heart failure, patients require frequent physical examination and judicious monitoring of their hemodynamic status to optimize therapy. Unfortunately, patients with compensated heart failure often do not have physical findings of high filling pressures, so the reliability of the physical examination is limited.2–4 Furthermore, the inability to detect worsening heart failure (ie, before a patient experiences dyspnea; gains weight; or has increased jugular venous distension, organ distension, especially in the lungs or liver, and peripheral edema) results in treatment delays or frequent hospital admissions with invasive and expensive therapeutic interventions. Indirect hemodynamic assessment through noninvasive techniques such as echocardiography can provide information on left ventricular ejection fraction as well as qualitative and quantitative measurements of the cardiac structures.
However, direct measurement of hemodynamic parameters via right-sided heart catheterization is the most objective and preferred standard for guiding therapy for heart failure. Right-sided heart pressures provide diagnostic, therapeutic, and prognostic information in the treatment of heart failure. But right-sided heart catheterization is often inconvenient, associated with significant risks, limited to the acute care setting, and only provides data when patients are supine. Consequently, the benefit of a convenient, continuous, objective, and ambulatory method for measuring hemodynamic pressures is widely supported in the management of heart failure therapy.
 |
The Implantable Hemodynamic Monitoring System
|
|---|
The implantable hemodynamic monitoring system (IHMS) known as the Chronicle (Medtronic, Inc, Minneapolis, Minn) measures and records hemo-dynamic pressures and associated clinical data. The device has most recently completed a multi-center phase 3 clinical trial; approval of the device in 2005 by the Food and Drug Administration is anticipated. The monitoring system consists of an implantable, computerized electrical device, which resembles a pacemaker (the implantable hemodynamic monitor or IHM), connected to a specialized right ventricular lead (Figure 1
). The IHM contains a lithium–manganese dioxide power source, integrated circuitry, and a radiofrequency transmission coil sealed in a titanium can. The right ventricular lead is an insulated metal wire with a unipolar pressure sensor tip. An external programmer is used to set the monitor functions. The device can continuously store data or record real-time beat-to-beat signals, providing an instantaneous hemodynamic profile.
View larger version (101K):
[in this window]
[in a new window]
|
Figure 1 The implantable hemodynamic monitor. The Chronicle implantable hemodynamic monitor is an investigational device, limited by United States law to investigational use.
Illustration courtesy of Medtronic, Inc.
|
|
Real-time waveform data are accessed via the programmer. Each patient carries a pagerlike device called an external pressure reference that calibrates the IHM to changes in barometric pressure. Additionally, a telephone-sized device called the interactive remote monitor is given to each patient to allow remote (home) data downloads via the telephone to a central computer server. Data analysis can then be done by retrieving the stored data telemetrically via the Internet through a secured access site. Figure 2 shows the components of the IHMS.
View larger version (28K):
[in this window]
[in a new window]
|
Figure 2 Components of the implantable hemodynamic monitoring (IHM) system.
Illustration courtesy of Medtronic, Inc.
|
|
|
Nursing Considerations Associated With Use of the Implantable Hemodynamic Monitoring System
|
|---|
The IHM is implanted via a simple outpatient surgical procedure similar to insertion of a conventional transvenous pacemaker. Patients are given a local anesthetic, and the IHM is implanted in a pectoral pocket of the upper left side of the chest. The right ventricular lead is implanted in the high-velocity blood flow region of the right ventricular outflow tract to minimize development of thrombus or fibrous growth around the sensor. Care is taken in placing the lead within the subclavian vein to prevent clamping the body of the lead between the clavicle and the first rib, which can cause lead fracture over time. Figure 3 is a radiographic illustration of an IHM in place. Potential complications associated with placement of the IHM are as follows:
View larger version (78K):
[in this window]
[in a new window]
|
Figure 3 Radiographic illustration of IHM placement.
Abbreviations: IHM, implantable hemodynamic monitor; RV, right ventricle.
|
|
- dysrhythmias,
- thrombosis or embolism,
- tamponade or perforation of the myocardium,
- hematoma or hemorrhage,
- lead fracture,
- pneumothorax, and
- infection.
Nursing care of patients after the procedure is the same as that for patients who have implantation of a permanent transvenous pacemaker. Antibiotics may be prescribed pro-phylactically. Restrictions in movement may be ordered to reduce the chance of lead displacement. Passive range-of-motion exercises help prevent frozen shoulder. The incision site should be observed for formation of pocket hematomas. For patients’ comfort, the head of bed should be elevated 20° to 30° to minimize swelling. Pain medication may be given as needed.
Maintenance of the IHMS does not differ from that of a permanent pacemaker. Gradual resumption of activities according to each patient’s tolerance is encouraged. Activities involving abrupt, forceful arm movement may result in lead fracture and may be limited for several weeks. Contact sports typically are not allowed. Certain procedures such as electrocautery and nuclear magnetic resonance imaging are contraindicated. Periodic checks help determine when a new battery is needed; currently, batteries last approximately 3 years. Although no direct health risk is associated with use of the IHM, potential risks include the following:
- tissue overgrowth of the lead,
- dislodgement of the lead,
- interference with data collection by the sensor (may result in data loss), and
- malfunction of external components.
|
Hemodynamic Measurements
|
|---|
The pressure sensor uses a titanium diaphragm and a polyurethane window to detect various hemodynamic parameters and associated clinical data (Table 1). Estimated pulmonary artery diastolic pressure is calculated from the points in the cardiac cycle where the pressure in the right ventricle equals the pressure in the pulmonary artery, which occurs at the end of ventricular isovolumetric contraction. Changes in the systolic and diastolic pressure tracing reflect right ventricular contraction. During contraction of the right ventricle, the pulmonary valve opens when right ventricular pressure exceeds pulmonary pressure, and ejection begins. Because flow into the pulmonary artery begins at this point, the pulmonary artery pressure is at its end-diastolic level. Additionally, the maximum rate of contraction (dP/dt, change in pressure divided by change in time) occurs at the same time that isovolumetric contraction ends (ie, the pulmonic valve opens) and flow into the pulmonary artery begins. The IHM can detect the point of maximum dP/dt and record the simultaneous right ventricular pressure from the sensor of the right ventricular lead. Thus, on the basis of the relationship between the right ventricular pressure and the pulmonary artery diastolic pressure, estimated pulmonary artery diastolic pressure is measured.5–7 Figure 4 illustrates these events in relation to the cardiac cycle.
View larger version (33K):
[in this window]
[in a new window]
|
Figure 4 The relationship of the cardiac cycle to PA pressure, RV pressure, and ventricular contraction. ePAD is calculated at the point where RV pressure = PA pressure.
Abbreviations: ECG, electrocardiogram; ePAD, estimated pulmonary artery diastolic pressure; PA, pulmonary artery; PASP, pulmonary artery systolic pressure; PEI, preejection interval; RR interval, beat-to-beat signals; RV, right ventricle; RV +dP/dt, right ventricular contraction; RV -dP/dt, right ventricular relaxation; RVDP, right ventricular diastolic pressure; RVSP, right ventricular systolic pressure; STI, systolic time interval.
Illustration courtesy of Medtronic, Inc.
|
|
In patients without valvular insufficiency, mitral stenosis, or pulmonary vascular disease, the estimated pulmonary artery diastolic pressure serves as a measure of pulmonary artery diastolic pressure, which reflects left ventricular end-diastolic pressure or left ventricular preload6 (Figure 5). Figure 6 illustrates a real-time recording from the IHM with the programmer. Figure 7 shows trends in elevated hemodynamic pressure.
View larger version (38K):
[in this window]
[in a new window]
|
Figure 5 From the RV pressure sensor, the ePAD is measured. ePAD = PA diastolic pressure = LA pressure, and LV end-diastolic pressure = LV preload.
Abbreviations: Ao, aorta; ePAD, estimated PA diastolic pressure; LA, left atrium; LV, left ventricle; PA, pulmonary artery; PCW, pulmonary capillary wedge pressure; RA, right atrium; RV, right ventricle.
Illustration courtesy of Medtronic, Inc.
|
|
View larger version (30K):
[in this window]
[in a new window]
|
Figure 6 Real-time recording of the implantable hemodynamic monitor with the programmer.
Illustration courtesy of Medtronic, Inc.
|
|
View larger version (66K):
[in this window]
[in a new window]
|
Figure 7 Elevated hemodynamic trends over a 1-month period downloaded by remote monitoring and reviewed by a clinician on a secured Internet site.
Abbreviations: ePAD, estimated pulmonary artery diastolic pressure; RV, right ventricle.
Illustration courtesy of Medtronic, Inc.
|
|
|
Research
|
|---|
The IHM has been under development for more than a decade.6,8–13 Earlier designs included sensors for right ventricular oxygen saturation and pulmonary artery sensors.9 But because of long-term safety considerations such as thrombus formation associated with sensors for venous oxygen saturation, technical problems associated with these leads, and the accumulated experience with the safety of right ventricular pacemaker leads, these early designs were abandoned in favor of a single right ventricular sensor lead.7 Newer designs are safer, have greater long-term accuracy, and are more reliable than the earlier designs.14,15
In the phase 1 multicenter clinical trial, 32 patients with heart failure had an IHM implanted.14 A total of 617 IHM recordings during a 1-year period were compared simultaneously with measurements obtained via pulmonary artery catheters while patients were at rest in the supine position, performing Valsalva maneuvers, and exercising (upright bicycle). Correlations between the 2 types of measurements were excellent14: right ventricular systolic pressure, r = 0.95; right ventricular diastolic pressure, r = 0.87; and estimated pulmonary artery diastolic pressure, r = 0.87. Device- and procedure-related adverse events included the following: pressure sensor failure (0.03%), complete heart block requiring a pacemaker (0.03%), pneumothorax (0.03%), hematoma of the device pocket (0.03%), and infection of the incision line (0.03%).14 No incidents of thrombus formation were evident in this study,14 which supported findings from earlier studies.10–13,15 Table 2 summarizes IHMS clinical trials to date. Figures 8 and 9 illustrate participants’ heart failure functional class and quality-of-life scores.
View larger version (17K):
[in this window]
[in a new window]
|
Figure 8 Change in New York Heart Association class of heart failure.
Illustration courtesy of Medtronic, Inc.
|
|
In a more recent multicenter study,15 32 patients with heart failure had an IHM implanted. Baseline hemodynamic parameters were evaluated during a 9-month period and were unavailable for making decisions about patients’ therapy. Hemodynamic parameters, clinical events, and effect on hospitalizations were then studied during a 17-month period when the IHM data were available for making clinical decisions. Findings revealed increases and decreases in right ventricular pressures correlated with volume overload and depletion, respectively. A 20% increase occurred in at least 1 hemodynamic measurement (right ventricular systolic pressure, right ventricular diastolic pressure, estimated pulmonary artery diastolic pressure) in 75% of clinical events 2 to 4 days before exacerbation of heart failure. In all exacerbations, hemodynamic pressures increased 24 hours before clinical intervention was implemented. Mean hospitalizations were 1.08 per patient-year when the IHM data were unavailable for making decisions about patients’ therapy and 0.47 per patient-year (a 57% reduction in hospitalization per patient-year, P<.01) when the IHM data were available.
|
Implications
|
|---|
Although the cost of the IHMS has yet to be determined, the benefits to clinicians of having objective hemodynamic parameters and associated clinical data both in real time and during a specified period is clear. The ability to continuously monitor hemodynamic pressures during "one time snap shot" measurements is by far superior to current assessment methods in heart failure therapy.18 The IHMS can be used to evaluate a patient’s response to therapy or to optimize pharmacological agents used to treat heart failure. Treatment can be individualized according to each patient’s hemodynamic response.
In addition, the activity level feature, a formulated numerical scale, allows clinicians to evaluate hemodynamic pressures in everyday ambulatory conditions. Of particular importance is the ability to detect changes in right ventricular pressures 24 hours before physical deterioration. These "early warning profiles" (right ventricular pressures and estimated pulmonary artery diastolic pressure monitored in real time or remotely) can prevent delays in treatment and prompt appropriate interventions before hemodynamic decompensation occurs.
The IHMS may also provide a means to objectively evaluate physiological effects of therapy in addition to specific events that may affect therapy. For example, a patient with heart failure celebrated a Super Bowl football game by indulging in nachos with cheese and beer. In a review of his hemodynamic data from the Internet Web site, this event was indicated by the IHMS within 24 hours by elevated pressures, although the patient had no symptoms. An extra dose of diuretics was prescribed for the next 3 days, and the patient’s hemodynamic pressures returned to baseline values (Figure 10). The additional benefit of being able to telephonically transmit data may result in improved quality of life, possibly resulting in fewer visits to a physician, clinic, or hospital, the elimination of right-sided heart catheterization, and a higher functional status due to optimization of hemodynamic status. Applications of the IHMS include the following19:
View larger version (52K):
[in this window]
[in a new window]
|
Figure 10 Evidence of elevated pressures with corresponding decline in pressures after treatment in a noncompliant patient with heart failure.
Abbreviations: ePAD, estimated pulmonary artery diastolic pressure; RV, right ventricle.
Illustration courtesy of Medtronic, Inc.
|
|
- individualized and tailored therapy for patients with heart failure
- early warning of deterioration in hemodynamic status,
- diagnosis of symptomatic events in the outpatient setting (home or clinic), and
- a method for using chronic hemodynamic data for long-term management of patients.
Physiological monitoring of hemodynamic pressures is no longer confined to the critical care unit. The IHMS connects patients through telehealth monitoring to clinics, physicians’ offices, disease management companies, and home health-care agencies. The role of nurses in successfully incorporating this technology into practice is crucial. Educating healthcare providers about the physiological measurements, interpreting the importance of these measurements in each patient, and determining the trends of the data are the start of a shift in the management of patients with heart failure. Additionally, educating patients about this technology, promoting self-regulating behaviors, and addressing issues related to home physiological monitoring present a unique challenge to nurses. Nursing research initiatives can focus on these issues, in addition to quality of life.
|
Conclusion
|
|---|
The IHMS provides objective hemodynamic and associated clinical data both in real time via a programmer and telephonically to a central computer site where data can be viewed via the Internet. With the use of monitoring parameters, appropriate and timely interventions can be initiated to ensure optimal outcomes for patients. The impact of the IHMS, however, on mortality and morbidity of patients with heart failure remains unknown; further testing in larger clinical trials specifically designed to evaluate patients’ outcomes and quality of life is needed. Preliminary results are encouraging, and the IHMS may be a step in the management of patients with heart failure that moves beyond traditional care-delivery systems.
|
References
|
|---|
- Packer M, Cohn JN. Consensus recommendations for the management of chronic heart failure. Am J Cardiol. 1999;83(2A):1A–38A.[Medline]
- Stephenson LW, Perloff JK. The limited reliability of physical signs for estimating hemodynamics in chronic heart failure. JAMA. 1989;261:884–888.[Abstract]
- Chakko S, Waska D, Martinez H, et al. Clinical, radiographic, and hemodynamic correlations in chronic congestive heart failure: conflicting results may lead to inappropriate care. Am J Med. 1991;90:353–359.[Medline]
- McGee S. Physical examination of venous pressure: a critical review. Am Heart J. 1998;136:10–18.[Medline]
- Ohlsson A, Bennett T, Norlander R, Ryden J, Astrom H, Ryden L. Monitoring of pulmonary arterial diastolic pressure through a right ventricular pressure transducer. J Card Fail. 1995;1:161–168.[Medline]
- Reynolds DW, Bartelt N, Taepke RT, Bennett TD. Measurement of pulmonary artery diastolic pressure from the right ventricle. J Am Coll Cardiol. 1995;25:1176–1182.[Abstract]
- Chuang PP, Wilson RF, Homans DC, et al. Measurement of pulmonary artery diastolic pressure from a right ventricular pressure transducer in patients with heart failure. J Card Fail. 1996;2:41–46.[Medline]
- Nathan AW, Perry SG, Cochran T, Banim SO, Spurrell RA, Camm AJ. Ambulatory monitoring of pulmonary artery pressure: a preliminary clinical evaluation. Br Heart J. 1983;49:33–37.[Abstract/Free Full Text]
- Gibbs JSR, MacLachan D, Fox KM. A new system for pulmonary artery pressure recording. Br Heart J. 1992;68:230–235.
- Steinhaus DM, Lemery R, Bresnahan DR Jr, et al. Initial experience with an implantable hemodynamic monitor. Circulation. 1996;93:745–752.[Abstract/Free Full Text]
- Ohlsson A, Nordlander R, Bennet T, et al. Continuous ambulatory haemodynamic monitoring with an implantable system: the feasibility of a new technique. Eur Heart J. 1998;19:174–184.[Abstract/Free Full Text]
- Ohlsson A, Kubo S, Steinhaus D, et al. Continuous ambulatory monitoring of absolute right ventricular pressure and mixed venous oxygen saturation in patients with heart failure using an implantable haemodynamic monitor: results of a 1 year multicentre feasibility study. Eur Heart J. 2001;22:942–954.[Abstract/Free Full Text]
- Braunschweig F, Linde C, Erikson MJ, Hofman-Bang C, Ryden L. Continuous haemodynamic monitoring during withdrawal of diuretics in patients with congestive heart failure. Eur Heart J. 2002;23:59–69.[Abstract/Free Full Text]
- Magalski A, Adamson PB, Gadler F, et al. Continuous ambulatory right heart pressure measurements with an implantable hemodynamic monitor: a multicenter, 12-month follow-up study of patients with chronic heart failure. J Card Fail. 2002;8:63–70.[Medline]
- Adamson PB, Magalski A, Braunschweig F, et al. Ongoing right ventricular hemodynamics in heart failure: clinical value of measurements derived from an implantable monitoring system. J Am Coll Cardiol. 2003;41:565–571.[Abstract/Free Full Text]
- Bennett T, Kjellstrom B, Taepke R, Ryden L. Development of implantable devices for continuous ambulatory monitoring of central hemodynamic values in heart failure patients. Pacing Clin Electrophysiol. 2005;28:573–584.[Medline]
- Medscape resource page. Compass-HF Trial finds continuous monitoring of intracardiac pressure associated with significant reduction in heart failure hospitalization. Available at: http://www.medscape.com/viewarticle/501568. Accessed July 29, 2005.
- Shabetai R. Monitoring heart failure hemodynamics with an implanted device: its potential to improve outcome. J Am Coll Cardiol. 2003;41:572–573.[Free Full Text]
- Braunschweig F, Linde C. Continuous hemodynamic monitoring in heart failure. J Cardiovasc Electrophysiol. 2002;13(suppl 1): S68–S72.[Medline]
Top
The Implantable Hemodynamic...
Nursing Considerations...
